Application of Amide Proton Transfer-weighted Imaging in Predicting Pathological Complete Response After Neoadjuvant Therapy of Rectal Cancer
NCT ID: NCT06719414
Last Updated: 2024-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
320 participants
OBSERVATIONAL
2024-10-22
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
• Does amide proton transfer-weighted imaging predict the cancer response before surgery? Participants will underwent amide proton transfer-weighted imaging as part of their regular MRI examination.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received neoadjuvant therapy before surgery
* Complete radical resection of rectal cancer and postoperative pathological examination
* Informed consent and signed the informed consent form
Exclusion Criteria
* Complicated with intestinal obstruction, intestinal perforation and other cases requiring surgical treatment
* The interval between preoperative MRI and surgery was more than 2 weeks
* Prior treatment for rectal cancer
* History of other malignant tumors
* Patients who cannot undergo MRI examination due to contraindications or relative contraindications
* Patients were lost to follow-up or voluntarily withdrew from the study due to adverse reactions or other reasons
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xinyi People's Hospital/Sixth Affiliated Hospital, Sun Yat-sen University Yuexi Hospital
UNKNOWN
Sixth Affiliated Hospital, Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Peiyi Xie
associate chief physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Xinyi People's Hospital
Maoming, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Pieyi Xie
Role: primary
Xi Li
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024ZSLYEC-552
Identifier Type: -
Identifier Source: org_study_id